BenzingaSeptember 10, 2026 at 9:28 AM NYLast Month
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
